Kenneth J. Hillan - Insider Trading & Ownership

Entity
Individual
Location
C/O Achaogen, Inc., 7000 Shoreline Court, Suite 371, South San Francisco, CA
Summary
The estimated net worth of Kenneth J. Hillan is at least $204K dollars as of June 6, 2024. Kenneth J. Hillan is the Chief Therapeutics Officer of 23andMe Holding Co. and owns shares of 23andMe Holding Co. (ME) stock worth about $159K. Kenneth J. Hillan is the Director of SANGAMO THERAPEUTICS, INC and owns shares of SANGAMO THERAPEUTICS, INC (SGMO) stock worth about $44.8K.
All Insider Reports
All Insider Reports

Ownership of Kenneth J. Hillan

Symbol Company Relationship Holdings Value Past Year Net Change Change % Report Period
ME 23andMe Holding Co. Chief Therapeutics Officer $159K Jun 5, 2023
SGMO SANGAMO THERAPEUTICS, INC Director $44.8K Jun 4, 2024
ZYME Zymeworks Inc. Director Dec 7, 2023
ZYME Zymeworks BC Inc. Director May 6, 2021

Insider Transactions Reported by Kenneth J. Hillan:

Sym Company Class Transaction % Value $ * Price $ Shares Shares After Date Ownership
* An asterisk sign (*) next to the price indicates that the price is likely invalid.